Hanmi Pharm_한미약품 (CEO Kwon Se-Chang_권세창 and Woo Jong-soo_우종수), announced 23 new drug pipelines on Monday in efforts to relay accurate information to consumers and stockholders under its “open trust management” policy.

A pharmaceutical pipeline refers to a group of medicines under discovery or development, broadly categorized into four stages; discovery, pre-clinical, clinical trials and marketing.

The 23 new drug pipelines break down into 14 new bio-drugs and nine new synthetic drugs. The company also added nine new drug candidates to the pre-clinical stage.

The new candidates include a rare disease treatment on LAPSCOVERY, a platform technology that enhances the efficacy of bio-drugs, and an immune target anti-cancer antibody project using Pentambody, produced by Beijing Hanmi Pharmaceuticals.

Hanmi also introduced an anticancer drug pipeline that uses stem cells, developed jointly with AJU researchers, as part of its open innovation strategy.

Hanmi color-coded indications for each candidate disease, making it accessible and convenient for both citizens and stockholders. In the case of technology transfers, the website indicates each new drug according to the name of the partnering company. The company said it plans to update the information in real time, whenever changes occur.

The company placed the new drug pipelines on its website, under the “New Drug Pipeline” banner, stating that it would continue to use its site as a communication platform to the public.